Methotrexate and Ras methylation: a new trick for an old drug?

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Ras proteins are central to human cancer development and progression.
• Ras localization to cellular membranes is essential for its function.
• Ras membrane association is regulated by posttranslational modifications of its C-terminal CAAX motif, including farnesylation, proteolysis, and carboxyl methylation.

Purpose of the Study:

• To explore the Ras protein processing pathway as a target for anti-cancer drug development.
• To investigate the potential of inhibiting enzymes involved in Ras posttranslational modification beyond farnesylation.
• To examine the mechanism by which methotrexate, an established chemotherapeutic, may exert its anti-cancer effects.

Main Methods:

• The study focuses on the biochemical pathway of Ras posttranslational modification.
• It reviews the development of farnesyltransferase inhibitors and their clinical status.
• It discusses the potential role of inhibiting other enzymes in the Ras processing pathway, specifically carboxyl methylation.

Main Results:

• Farnesyltransferase inhibitors targeting Ras farnesylation are in clinical trials.
• There is growing interest in developing inhibitors for the other two enzymes in the Ras processing pathway: proteolysis and carboxyl methylation.
• Emerging evidence suggests that methotrexate may inhibit Ras carboxyl methylation.

Conclusions:

• The Ras posttranslational modification pathway is a promising target for novel anti-cancer therapies.
• Inhibiting Ras carboxyl methylation represents a potential therapeutic strategy.
• Methotrexate's mechanism of action may involve the inhibition of Ras carboxyl methylation, linking an old drug to a new therapeutic target.